Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gastric Cancer

  Free Subscription


04.02.2019

2 BMC Cancer
1 Eur J Surg Oncol
1 Int J Cancer
1 Int J Oncol
1 J Surg Oncol
2 Lancet Gastroenterol Hepatol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. XIE JW, Lu J, Wang JB, Lin JX, et al
    Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients.
    BMC Cancer. 2018;18:1021.
    PubMed     Text format     Abstract available

  2. WANG Y, Chen Y, Li X, Hu W, et al
    Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    BMC Cancer. 2018;18:691.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  3. XIONG B, Ma L, Huang W, Cheng Y, et al
    Efficiency of bursectomy in patients with resectable gastric cancer: An updated meta-analysis.
    Eur J Surg Oncol. 2019 Jan 21. pii: S0748-7983(19)30043.
    PubMed     Text format     Abstract available


    Int J Cancer

  4. KATZ LH, Levi Z, Twig G, Kark JD, et al
    Risk factors associated with gastroenteropancreatic neuroendocrine tumors in a cohort of 2.3 million Israeli adolescents.
    Int J Cancer. 2018;143:1876-1883.
    PubMed     Text format     Abstract available


    Int J Oncol

  5. NGABIRE D, Seong YA, Patil MP, Niyonizigiye I, et al
    Induction of apoptosis and G1 phase cell cycle arrest by Aster incisus in AGS gastric adenocarcinoma cells.
    Int J Oncol. 2018;53:2300-2308.
    PubMed     Text format     Abstract available


    J Surg Oncol

  6. RHOME RM, Ru M, Moshier E, Mazumdar M, et al
    Stage-matched survival differences by ethnicity among gastric cancer patients of Asian ancestry treated in the United States.
    J Surg Oncol. 2019 Jan 29. doi: 10.1002/jso.25389.
    PubMed     Text format     Abstract available


    Lancet Gastroenterol Hepatol

  7. ILSON DH
    Stage II gastric cancer: 1 year of S-1 remains standard of care.
    Lancet Gastroenterol Hepatol. 2019 Jan 21. pii: S2468-1253(18)30411.
    PubMed     Text format    

  8. YOSHIKAWA T, Terashima M, Mizusawa J, Nunobe S, et al
    Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
    Lancet Gastroenterol Hepatol. 2019 Jan 21. pii: S2468-1253(18)30383.
    PubMed     Text format     Abstract available


    PLoS One

  9. NAKAYAMA A, Abe H, Kunita A, Saito R, et al
    Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma.
    PLoS One. 2019;14:e0211358.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: